S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NYSE:DGX

Quest Diagnostics Competitors

$115.59
+0.96 (+0.84 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$114.20
Now: $115.59
$116.63
50-Day Range
$114.63
MA: $123.84
$133.34
52-Week Range
$73.02
Now: $115.59
$134.71
Volume1.51 million shs
Average Volume1.47 million shs
Market Capitalization$15.43 billion
P/E Ratio14.29
Dividend Yield1.95%
Beta1.07

Competitors

Quest Diagnostics (NYSE:DGX) Vs. LH, DVA, AMED, CHE, LHCG, and AMN

Should you be buying DGX stock or one of its competitors? Companies in the sub-industry of "health care services" are considered alternatives and competitors to Quest Diagnostics, including Laboratory Co. of America (LH), DaVita (DVA), Amedisys (AMED), Chemed (CHE), LHC Group (LHCG), and AMN Healthcare Services (AMN).

Quest Diagnostics (NYSE:DGX) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Analyst Ratings

This is a summary of current ratings for Quest Diagnostics and Laboratory Co. of America, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics09602.40
Laboratory Co. of America011402.93

Quest Diagnostics currently has a consensus price target of $129.00, indicating a potential upside of 11.60%. Laboratory Co. of America has a consensus price target of $235.4667, indicating a potential downside of 1.85%. Given Quest Diagnostics' higher probable upside, equities research analysts plainly believe Quest Diagnostics is more favorable than Laboratory Co. of America.

Risk and Volatility

Quest Diagnostics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 89.3% of Laboratory Co. of America shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by insiders. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Quest Diagnostics and Laboratory Co. of America's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
Laboratory Co. of America6.79%21.05%8.83%

Valuation and Earnings

This table compares Quest Diagnostics and Laboratory Co. of America's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.00$858 million$6.5617.62
Laboratory Co. of America$11.55 billion2.02$823.80 million$11.3221.19

Quest Diagnostics has higher earnings, but lower revenue than Laboratory Co. of America. Quest Diagnostics is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.

Summary

Laboratory Co. of America beats Quest Diagnostics on 10 of the 14 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Analyst Ratings

This is a summary of current ratings for Quest Diagnostics and DaVita, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics09602.40
DaVita04102.20

Quest Diagnostics currently has a consensus price target of $129.00, indicating a potential upside of 11.60%. DaVita has a consensus price target of $116.40, indicating a potential upside of 13.97%. Given DaVita's higher probable upside, analysts plainly believe DaVita is more favorable than Quest Diagnostics.

Risk and Volatility

Quest Diagnostics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, DaVita has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.

Insider & Institutional Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 91.7% of DaVita shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by insiders. Comparatively, 1.0% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Quest Diagnostics and DaVita's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
DaVita7.32%43.99%5.27%

Valuation and Earnings

This table compares Quest Diagnostics and DaVita's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.00$858 million$6.5617.62
DaVita$11.39 billion0.98$810.98 million$5.4018.91

Quest Diagnostics has higher earnings, but lower revenue than DaVita. Quest Diagnostics is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.

Summary

Quest Diagnostics beats DaVita on 8 of the 14 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and Amedisys (NASDAQ:AMED) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Risk and Volatility

Quest Diagnostics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Valuation and Earnings

This table compares Quest Diagnostics and Amedisys' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.00$858 million$6.5617.62
Amedisys$1.96 billion4.26$126.83 million$4.4057.65

Quest Diagnostics has higher revenue and earnings than Amedisys. Quest Diagnostics is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quest Diagnostics and Amedisys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
Amedisys8.22%26.41%12.43%

Insider & Institutional Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 85.9% of Amedisys shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by insiders. Comparatively, 2.8% of Amedisys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Quest Diagnostics and Amedisys, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics09602.40
Amedisys03902.75

Quest Diagnostics currently has a consensus price target of $129.00, indicating a potential upside of 11.60%. Amedisys has a consensus price target of $274.4615, indicating a potential upside of 8.21%. Given Quest Diagnostics' higher probable upside, equities research analysts plainly believe Quest Diagnostics is more favorable than Amedisys.

Summary

Amedisys beats Quest Diagnostics on 8 of the 14 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and Chemed (NYSE:CHE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.

Risk and Volatility

Quest Diagnostics has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Chemed has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Earnings and Valuation

This table compares Quest Diagnostics and Chemed's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.00$858 million$6.5617.62
Chemed$1.94 billion3.66$219.92 million$13.9531.91

Quest Diagnostics has higher revenue and earnings than Chemed. Quest Diagnostics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quest Diagnostics and Chemed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
Chemed13.11%38.13%21.70%

Dividends

Quest Diagnostics pays an annual dividend of $2.24 per share and has a dividend yield of 1.9%. Chemed pays an annual dividend of $1.36 per share and has a dividend yield of 0.3%. Quest Diagnostics pays out 34.1% of its earnings in the form of a dividend. Chemed pays out 9.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has raised its dividend for 1 consecutive years and Chemed has raised its dividend for 12 consecutive years.

Institutional & Insider Ownership

85.7% of Quest Diagnostics shares are held by institutional investors. Comparatively, 86.0% of Chemed shares are held by institutional investors. 1.5% of Quest Diagnostics shares are held by insiders. Comparatively, 4.0% of Chemed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Quest Diagnostics and Chemed, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics09602.40
Chemed00203.00

Quest Diagnostics presently has a consensus target price of $129.00, indicating a potential upside of 11.60%. Chemed has a consensus target price of $557.50, indicating a potential upside of 25.22%. Given Chemed's stronger consensus rating and higher probable upside, analysts clearly believe Chemed is more favorable than Quest Diagnostics.

Summary

Chemed beats Quest Diagnostics on 11 of the 17 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and LHC Group (NASDAQ:LHCG) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.

Volatility & Risk

Quest Diagnostics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, LHC Group has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.

Earnings and Valuation

This table compares Quest Diagnostics and LHC Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.00$858 million$6.5617.62
LHC Group$2.08 billion2.76$95.73 million$4.4740.65

Quest Diagnostics has higher revenue and earnings than LHC Group. Quest Diagnostics is trading at a lower price-to-earnings ratio than LHC Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quest Diagnostics and LHC Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
LHC Group5.00%9.71%6.51%

Insider & Institutional Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 91.8% of LHC Group shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by company insiders. Comparatively, 4.8% of LHC Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Quest Diagnostics and LHC Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics09602.40
LHC Group02702.78

Quest Diagnostics presently has a consensus target price of $129.00, indicating a potential upside of 11.60%. LHC Group has a consensus target price of $220.00, indicating a potential upside of 21.07%. Given LHC Group's stronger consensus rating and higher probable upside, analysts clearly believe LHC Group is more favorable than Quest Diagnostics.

Quest Diagnostics (NYSE:DGX) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.

Volatility & Risk

Quest Diagnostics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, AMN Healthcare Services has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Earnings and Valuation

This table compares Quest Diagnostics and AMN Healthcare Services' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.00$858 million$6.5617.62
AMN Healthcare Services$2.22 billion1.54$113.99 million$3.1822.92

Quest Diagnostics has higher revenue and earnings than AMN Healthcare Services. Quest Diagnostics is trading at a lower price-to-earnings ratio than AMN Healthcare Services, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quest Diagnostics and AMN Healthcare Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
AMN Healthcare Services3.78%20.38%6.87%

Insider & Institutional Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 94.6% of AMN Healthcare Services shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by company insiders. Comparatively, 1.4% of AMN Healthcare Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Quest Diagnostics and AMN Healthcare Services, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics09602.40
AMN Healthcare Services00703.00

Quest Diagnostics presently has a consensus target price of $129.00, indicating a potential upside of 11.60%. AMN Healthcare Services has a consensus target price of $76.2857, indicating a potential upside of 4.69%. Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than AMN Healthcare Services.

Summary

Quest Diagnostics beats AMN Healthcare Services on 9 of the 14 factors compared between the two stocks.


Quest Diagnostics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.6$239.91+1.4%$23.37 billion$11.55 billion27.93
DaVita logo
DVA
DaVita
2.0$102.13+0.0%$11.17 billion$11.39 billion15.31
Amedisys logo
AMED
Amedisys
1.2$253.64+3.7%$8.32 billion$1.96 billion50.83Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Chemed logo
CHE
Chemed
2.5$445.21+0.3%$7.10 billion$1.94 billion27.00Earnings Announcement
Dividend Announcement
Analyst Report
LHC Group logo
LHCG
LHC Group
1.7$181.71+3.5%$5.74 billion$2.08 billion55.23Earnings Announcement
High Trading Volume
News Coverage
Gap Up
AMN Healthcare Services logo
AMN
AMN Healthcare Services
1.3$72.87+1.1%$3.43 billion$2.22 billion38.97Insider Selling
R1 RCM logo
RCM
R1 RCM
1.6$27.64+0.7%$3.22 billion$1.19 billion307.15Insider Selling
News Coverage
MEDNAX logo
MD
MEDNAX
1.4$24.43+1.9%$2.09 billion$3.51 billion-2.83Analyst Report
Gap Up
The Providence Service logo
PRSC
The Providence Service
1.0$128.26+16.7%$1.82 billion$1.51 billion-2,137.31Gap Down
CorVel logo
CRVL
CorVel
0.8$101.50+0.0%$1.81 billion$592.22 million45.11Insider Selling
News Coverage
Tivity Health logo
TVTY
Tivity Health
1.0$23.80+1.6%$1.16 billion$1.13 billion-2.15Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Cross Country Healthcare logo
CCRN
Cross Country Healthcare
1.1$11.11+1.9%$417.33 million$822.22 million-21.37Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.7$3.25+0.0%$13.18 million$24.08 million-0.38Gap Down
This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.